Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Varenicline

Nature Reviews Drug Discovery volume 5, pages 537–538 (2006)Cite this article

Abstract

Varenicline tartrate (Chantix; Pfizer), an α4β2 nicotinic receptor partial agonist, was approved by the US FDA as an aid to smoking cessation treatment in May 2006.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Varenicline.

References

  1. Ezzati, M. et al. Estimates of global mortality attributable to smoking in 2000. Lancet 362, 847–852 (2003).

    Article  PubMed  Google Scholar 

  2. Henningfield, J. E. et al. Pharmacotherapy for nicotine dependence. CA Cancer J. Clin. 55, 281–299 (2005).

    Article  PubMed  Google Scholar 

  3. Dani, J. A. & Heinemann, S. Molecular and cellular aspects of nicotine abuse. Neuron 16, 905–908 (1996).

    Article  CAS  PubMed  Google Scholar 

  4. Picciotto, M. R. et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391, 173–177 (1998).

    Article  CAS  PubMed  Google Scholar 

  5. Tapper, A. R. et al. Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 306, 1029–1032 (2004).

    Article  CAS  PubMed  Google Scholar 

  6. Coe, J. W. et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48, 3474–3477 (2005).

    Article  CAS  PubMed  Google Scholar 

  7. FDA labelling information, [online] (2006).

  8. Piper, M. E. et al. A multiple motives approach to tobacco dependence: the Wisconsin Inventory of Smoking Dependence Motives (WISDM-68). J. Consult. Clin. Psychol. 72, 139–154 (2004).

    Article  PubMed  Google Scholar 

  9. Lancaster, T. et al. Prevention of relapse after quitting smoking: a systematic review of trials. Arch. Intern. Med. 166, 828–835 (2006).

    Article  PubMed  Google Scholar 

  10. Grant, B. F. et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry 61, 1107–1115 (2004).

    Article  PubMed  Google Scholar 

  11. Mackay, J. & Eriksen, M. The Tobacco Atlas. World Health Organization, [online] (2004).

  12. IMS Health, IMS MIDAS Quantum (Dec 2005).

Download references

Author information

Authors and Affiliations

  1. the Department of Psychiatry and Human Behavior, Butler Hospital, 345 Blackstone Boulevard, Providence, 02906, Rhode Island, USA

    Raymond Niaura

  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Carole Jones

  3. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Raymond Niaura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carole Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niaura, R., Jones, C. & Kirkpatrick, P. Varenicline. Nat Rev Drug Discov 5, 537–538 (2006). https://doi.org/10.1038/nrd2088

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2088

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing